Literature DB >> 19138884

Association of alleles at polymorphic sites in the Osteopontin encoding gene in young type 1 diabetic patients.

Renato Marciano1, Giuseppe D'Annunzio, Nicola Minuto, Lorenzo Pasquali, Andrea Santamaria, Marco Di Duca, Roberto Ravazzolo, Renata Lorini.   

Abstract

The Osteopontin (OPN) encoding gene, SPP1, can be considered as a candidate for genetic susceptibility to type 1 diabetes (T1D) because of its known function in immune response and inflammation. This work aimed to evaluate the role of SPP1 gene in susceptibility to T1D. Patients (238: 130 male, 108 female) and unaffected adult control individuals (137: 68 males and 69 females) have been genotyped for three variants in the SPP1 gene: -156 (G/GG) and -66 (T/G) in the promoter and a biallelic ins/del variant (TG/TGTG) at +245 in the first intron. The G allele at the -66 SNP had significantly higher frequency in controls than T1D patients. Interestingly, case-control comparison in males showed no significant association, whereas the association was confirmed in females. These results suggest that SPP1 can play a role as susceptibility gene, possibly by a sex-specific mechanism acting in the autoimmune process.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19138884     DOI: 10.1016/j.clim.2008.11.004

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  13 in total

Review 1.  Intracellular osteopontin (iOPN) and immunity.

Authors:  Makoto Inoue; Mari L Shinohara
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

2.  Genetic Modifiers for Neuromuscular Diseases.

Authors:  Kay-Marie Lamar; Elizabeth M McNally
Journal:  J Neuromuscul Dis       Date:  2014

3.  SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy.

Authors:  E Pegoraro; E P Hoffman; L Piva; B F Gavassini; S Cagnin; M Ermani; L Bello; G Soraru; B Pacchioni; M D Bonifati; G Lanfranchi; C Angelini; A Kesari; I Lee; H Gordish-Dressman; J M Devaney; C M McDonald
Journal:  Neurology       Date:  2010-12-22       Impact factor: 9.910

4.  The osteopontin transgenic mouse is a new model for Sjögren's syndrome.

Authors:  Sehba Husain-Krautter; Jill M Kramer; Wentian Li; Benchang Guo; Thomas L Rothstein
Journal:  Clin Immunol       Date:  2015-01-05       Impact factor: 3.969

5.  Expression-based Genome-wide Association Study Links OPN and IL1-RA With Newly Diagnosed Type 1 Diabetes in Children.

Authors:  Xiaofan Jia; Kyoko Toda; Ling He; Dongmei Miao; Satoru Yamada; Liping Yu; Keiichi Kodama
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

Review 6.  Interstitial calcinosis in renal papillae of genetically engineered mouse models: relation to Randall's plaques.

Authors:  Xue-Ru Wu
Journal:  Urolithiasis       Date:  2014-08-06       Impact factor: 3.436

7.  A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease.

Authors:  Walter Maetzler; Joan Michelis; Juergen Tomiuk; Arthur Melms; Clemens Becker; Thomas Gasser; Claudia Schulte; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2009-04-02       Impact factor: 3.575

8.  Association between polymorphisms in osteopontin gene (SPP1) and first episode calcium oxalate urolithiasis.

Authors:  Mohammad Reza Safarinejad; Nayyer Shafiei; Shiva Safarinejad
Journal:  Urolithiasis       Date:  2013-06-20       Impact factor: 3.436

9.  The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn's disease.

Authors:  Jürgen Glas; Julia Seiderer; Corinna Bayrle; Martin Wetzke; Christoph Fries; Cornelia Tillack; Torsten Olszak; Florian Beigel; Christian Steib; Matthias Friedrich; Julia Diegelmann; Darina Czamara; Stephan Brand
Journal:  PLoS One       Date:  2011-12-29       Impact factor: 3.240

10.  Association between Osteopontin Promoter Gene Polymorphisms and Haplotypes with Risk of Diabetic Nephropathy.

Authors:  Balneek Singh Cheema; Sreenivasa Iyengar; Rajni Sharma; Harbir Singh Kohli; Anil Bhansali; Madhu Khullar
Journal:  J Clin Med       Date:  2015-06-10       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.